T-钙黏蛋白联合顺铂对顺铂耐药的黑色素瘤细胞的影响  

Effect of T-cadherin Combined with Cisplatin on Cisplatin-resistant Melanoma Cells

作　　者：陆海涛[1] 郭健[1] 刘利君[1] 牛艳东[1] 段昕所[1] LU Haitao;GUO Jian;LIU Lijun;NIU Yandong;DUAN Xinsuo(Department of Dermatology,the Affiliated Hospital of Chengde Medical College,Chengde 067000,China)

机构地区：[1]承德医学院附属医院皮肤性病科,承德067000

出　　处：《医药导报》2020年第5期594-598,共5页Herald of Medicine

基　　金：河北省医学科学研究计划项目(2020364)。

摘　　要：目的:探讨T-钙黏蛋白(T-cadherin)联合顺铂对顺铂耐药的黑色素瘤细胞株的影响。方法:采用大剂量冲击、逐步增加剂量相结合的方法诱导B16F10顺铂耐药细胞株(CDDP-R B16F10)。将T-钙黏蛋白转染CDDP-R B16F10,采用免疫组化链霉菌抗生物素蛋白-过氧化物酶连结(SP)法检测CDDP-R B16F10细胞T-钙黏蛋白的表达;噻唑蓝(MTT)法和流式细胞术检测T-钙黏蛋白联合顺铂对CDDP-R B16F10细胞增殖和凋亡的影响。结果:免疫组化SP法结果显示,T-钙黏蛋白呈阳性表达,证实T-钙黏蛋白已成功转染于肿瘤细胞。pEGFP-N1-T-cadherin联合顺铂组CDDP-R B16F10细胞增殖抑制率61.5%,凋亡率(19.43±2.52)%,均显著高于其他组(均P<0.05)。结论:T-钙黏蛋白联合顺铂可抑制CDDP-R B16F10增殖,促进CDDP-R B16F10凋亡;T-钙黏蛋白可逆转顺铂耐药的黑色素瘤细胞株对顺铂的耐药性。Objective:To investigate the effect of T-cadherin combined with cisplatin(cis-diaminodichloroplatinum,CDDP)on cisplatin resistant melanoma cell line.Methods:CDDP resistance B16F10(CDDP-R B16F10)was induced by exposure to high and gradually increased dose of CDDP.The T-cadherin plasmid was transfected into CDDP-R B16F10.The expression of T-cadherin was measured by streptavidin-peroxidase(SP)of immunohistochemistry method.The effects of T-cadherin combined with cisplatin on proliferation and apoptosis of CDDP-R B16F10 were determined by MTT assay and flow cytometry.Results:The protein of T-cadherin could be detected in T-cadherin transfected cells by immunohistochemistry SP method.The inhibition rate of the proliferation apoptosis of pEGFP-N1-T-cadherin combined with cisplatin group(61.5%)was obviously higher than that of other groups(P<0.05),and the apoptosis rate(19.43±2.52)%was significantly higher than that of other groups(P<0.05).Conclusion:T-cadherin combined with cisplatin can inhibit the proliferation of CDDP-R B16F10 cells and induce apoptosis of CDDP-R B16F10 cells.T-cadherin can reverse the cisplatin resistance of CDDP-R B16F10.

关 键 词：T-钙黏蛋白 顺铂 黑色素瘤 耐药 

分 类 号：R979.1[医药卫生—药品] R965[医药卫生—药学]